-
US Vice President Vance departs for Hungary in support of Orban
-
Ex-top aide of Spanish PM set to go on trial for graft
-
Tokyo confirms Japanese national held by Iran freed
-
AI-generated artists break through in country music
-
Rio de Janeiro's gangs hijack buses to sow chaos in war with police
-
Iran defiant as deadline looms for Trump threat to infrastructure
-
Tiger's treatment battle in thoughts of stars at Masters
-
Thai amateur 'Fifa' ready for Masters kick-off
-
'Hacks' has 'perfect' ending after 5 seasons, says star Smart
-
Age and near misses don't worry Rose in Masters quest
-
'Incredibly dangerous': rescuing downed fighter crew in Iran
-
Wall Street stocks rise on hopes for US-Iran ceasefire
-
High-flying Villarreal stumble at Girona
-
Promoter defends plan for Kanye West to headline London fest
-
Napoli's Serie A title defence boosted by beating AC Milan
-
Trump lashes out at 'paper tiger' NATO while re-upping Greenland claim
-
Reed finds DP World Tour success after leaving LIV
-
Lunar crater named after Artemis commander's deceased wife
-
WNBA star Reese joining Atlanta from Chicago: club
-
Gotterup seeks rare win in Masters debut
-
Bayern's Kompany waiting on Kane for 'toughest' game at Real Madrid
-
Juve beat Genoa to close in on Serie A top four
-
'Historic day': Artemis astronauts break space distance record
-
Augusta already firm and fast ahead of 90th Masters
-
French hope Seixas storms Basque Tour time-trial opener
-
Trump says Iran ceasefire proposal 'very significant step'
-
Wawrinka falls in first round on Monte Carlo farewell
-
Greece PM calls on European prosecutor to act 'without delay' on agriculture fraud
-
US Democratic lawmakers slam 'economic bombing' after Cuba visit
-
Red Cross chief condemns 'deliberate threats' against civilians in Mideast war
-
Giant step for humankind: Artemis crew to set space distance record
-
Wawrinka falls in first round of Monte Carlo Masters
-
Ex-England rugby international Lawes to leave Brive
-
Fit-again Mbappe at Real Madrid for clashes like Bayern tie: Arbeloa
-
Swimmers McKeown, O'Callaghan and Chalmers dominate at Australian Open
-
Bucha: When the Russian killers came...
-
Iran, a Terrorist State with No Right to Exist
-
African players in Europe: Semenyo scores as City rout Liverpool
-
Israeli strikes kill Iran Guards intel chief as Trump deadline looms
-
Saving energy in everyday life or a complete rip-off?
-
US sprint star Richardson wins Australia's Stawell Gift in record time
-
Rockets down Warriors in Curry return, Flagg carries Mavs past Lakers
-
Artemis mission approaches lunar loop for first flyby since 1972
-
Israeli rescuers search for missing in building strike, two dead
-
Defiant Iran ramps up attacks after Trump warning
-
Saudi oasis town adjusts to life in the firing line
-
Pogacar stays humble with Monument history beckoning
-
Real Madrid hoping Champions League magic halts Bayern juggernaut
-
Sputtering Arsenal face test of character in Sporting clash
-
'Not the Cairo we know': Energy shock from Iran war dims Egypt nights
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Anderson--AT